<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="than 1 million lives worldwide. Accumulating evidence suggests that SARS-CoV-2" exact="infection" post="can lead to a variety of clinical conditions, ranging"/>
 <result pre="patients subsequently die. Insights into the pathogenic mechanisms underlying SARS-CoV-2" exact="infection" post="and COVID-19 progression are emerging and highlight the critical"/>
 <result pre="mechanisms involved in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="and the progression of coronavirus disease 2019 (COVID-19), focusing"/>
 <result pre="systemic thrombosis, seem to be more promising approaches to the" exact="treatment" post="of severe COVID-19. Subject terms Kidney diseases Infectious diseases"/>
 <result pre="non-endosomal entry at the plasma membrane may be an additional" exact="infection" post="route for SARS-CoV-2. Within the target cells, SARS-CoV-2 is"/>
 <result pre="as well as several accessory proteins with unknown functions1,6. SARS-CoV-2" exact="infection" post="(Fig.Â 1c) begins when the viral spike protein attaches"/>
 <result pre="the current understanding of the pathogenic mechanisms involved in SARS-CoV-2" exact="infection" post="and progression of COVID-19, focusing on the critical role"/>
 <result pre="examine emerging data in support of a role for SARS-CoV-2" exact="infection" post="in inducing widespread endothelial damage, complement-associated blood clotting and"/>
 <result pre="may be repurposed to treat severe cases of COVID-19. SARS-CoV-2" exact="infection" post="and COVID-19 The human-to-human transmission of SARS-CoV-2 is primarily"/>
 <result pre="within 6â€&quot;10 days. However, in almost 20% of patients viral" exact="infection" post="progresses down the trachea to the lungs21. Within the"/>
 <result pre="owing to their substantial expression of ACE2 and TMPRSS2. SARS-CoV-2" exact="infection" post="induces these epithelial cells to undergo apoptotic cell death"/>
 <result pre="suggests that a suboptimal or unrestrained immune response during SARS-CoV-2" exact="infection" post="drives the clinical patterns, disease severity and progression of"/>
 <result pre="Fig. 2 Pathogenesis and outcomes of COVID-19. a | Following" exact="infection" post="of the lungs, (severe acute respiratory syndrome coronavirus 2"/>
 <result pre="distress syndrome. The generation of excess cytokines and persistent viral" exact="infection" post="leads to systemic vascular damage, disseminated intravascular coagulation (DIC)"/>
 <result pre="mitochondrial membrane is essential for the activation of IFN-I after" exact="infection" post="of RNA viruses49, and it is possible that SARS-CoV-2"/>
 <result pre="translocation and IFN-I activation50. In support of this hypothesis, SARS-CoV-2" exact="infection" post="is associated with lower IFN-I and IFN-III levels and"/>
 <result pre="secondary haemophagocytic lymphohistiocytosis, and consequently, the immune response to SARS-CoV-2" exact="infection" post="was initially considered to involve a form of cytokine"/>
 <result pre="SARS-CoV-2 spike proteins interact with CD68+ macrophages, suggesting direct viral" exact="infection" post="of these cells59. Single-cell RNA sequencing of immune cells"/>
 <result pre="macrophages61. Moreover, use of untargeted metabolomics has shown that SARS-CoV-2" exact="infection" post="triggers profound alterations in macrophage phenotype and function by"/>
 <result pre="fluid cells from eight patients with COVID-19 suggested that SARS-CoV-2" exact="infection" post="elicits more pronounced neutrophil infiltration than other forms of"/>
 <result pre="that the rise in inflammatory cytokine levels induced by SARS-CoV-2" exact="infection" post="might drive the depletion of T and NK cells,"/>
 <result pre="load and hyperactivation of the innate response77 (Fig.Â 2b). Severe" exact="infection" post="caused by SARS-CoV-2 has been likened to lymphopenic community-acquired"/>
 <result pre="immunity89â€&quot;91. Non-human primates reinfected with SARS-CoV-2 &amp;lt;1â€‰month after their first" exact="infection" post="displayed a reduced viral load and prevented disease recurrence"/>
 <result pre="beneficial effects were associated with potent neutralizing antibody responses. Moreover," exact="treatment" post="with two potent human monoclonal antibodies that recognize the"/>
 <result pre="in a preprint study, longitudinal evaluation of patients with SARS-CoV-2" exact="infection" post="reported a rapid decline in levels of neutralizing antibody"/>
 <result pre="adaptive immunity, including the cellular and humoral response to SARS-CoV-2" exact="infection" post="(Fig.Â 2). These findings indicate the need for further"/>
 <result pre="that children may be at a lower risk of SARS-CoV-2" exact="infection" post="than adults owing to the lower expression of ACE2"/>
 <result pre="lavage or nasopharyngeal aspirates, but laboratory tests were indicative of" exact="infection" post="and inflammation, including high levels of C-reactive protein, ferritin"/>
 <result pre="of ACE2 expression by endothelial cells in response to SARS-CoV-2" exact="infection" post="leads to reduced generation of Ang 1â€&quot;7 and consequently,"/>
 <result pre="reported by a preprint study135. Fig. 3 Effect of SARS-CoV-2" exact="infection" post="on endothelial cell function, systemic coagulation and thrombosis. a"/>
 <result pre="activation â€&quot; for example, in the context of prolonged SARS-CoV-2" exact="infection" post="â€&quot; can be detrimental by causing direct damage of"/>
 <result pre="available data on complement activation in the context of coronavirus" exact="infection" post="are derived from the SARS and MERS epidemics. A"/>
 <result pre="cytotoxicity143; however, whether this process is also activated following SARS-CoV-2" exact="infection" post="is unknown. Use of an ultra-high-throughput clinical proteomic approach"/>
 <result pre="from another study suggest that enhanced IgA levels during SARS-CoV-2" exact="infection" post="might act synergistically with IgG to promote antibody-dependent cytotoxicity108."/>
 <result pre="pathway-mediated cytotoxicity. Although clinical insights into complement activation following SARS-CoV-2" exact="infection" post="are limited145, the above findings indicate that unrestrained complement"/>
 <result pre="role in outcomes following SARS-CoV-2 infection148. Indeed, patients with SARS-CoV-2" exact="infection" post="are at an increased risk of widespread coagulation of"/>
 <result pre="in COVID-19 The lungs are the main site for SARS-CoV-2" exact="infection" post="and the first affected organ in COVID-19. However, sustained"/>
 <result pre="target organ for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="by several studies. a | Within the glomerulus, podocytes"/>
 <result pre="high levels of ACE2 in the apical brush border. SARS-CoV-2" exact="infection" post="leads to loss of the brush border and vacuolar"/>
 <result pre="that they are potential SARS-CoV-2 targets173,174. ACE2 internalization following SARS-CoV-2" exact="infection" post="could induce an imbalance in the reninâ€&quot;angiotensinâ€&quot;aldosterone system, with"/>
 <result pre="the kidney14,175. The critical role of ACE2 in SARS-CoV-2 kidney" exact="infection" post="is emphasized by findings from in vitro studies that"/>
 <result pre="that SARS-CoV-2 can infect human kidney organoids and that this" exact="infection" post="can be limited by expression of human recombinant soluble"/>
 <result pre="and systemic microangiopathy. Antiviral therapies The first week following SARS-CoV-2" exact="infection" post="â€&quot; during which the virus enters alveolar cells and"/>
 <result pre="the lungs â€&quot; represents a critical time for blocking the" exact="infection" post="using antiviral agents. Of the repurposed antivirals investigated to"/>
 <result pre="selectivity, a randomized, controlled, open-label trial reported no differences between" exact="treatment" post="with lopinavirâ€&quot;ritonavir and standard care in time to clinical"/>
 <result pre="prophylaxis strategy202. Moreover, two clinical trials have shown that hydroxychloroquine" exact="treatment" post="poses serious safety concerns, increasing the risk of cardiovascular"/>
 <result pre="prolonged virus shedding207. However, early reports from China indicated that" exact="treatment" post="with methylprednisolone decreased the risk of death of patients"/>
 <result pre="of immunoglobulin after hospital admission reduced morbidity and rates of" exact="treatment" post="failure211â€&quot;213. A preliminary study found that an early, short"/>
 <result pre="receiving no respiratory support216. These findings are encouraging since dexamethasone" exact="treatment" post="is also highly beneficial in patients with pre-existing chronic"/>
 <result pre="For example, the observed suppression of interferon responses following SARS-CoV-2" exact="infection" post="suggests that interferon supplementation may be a potential therapeutic"/>
 <result pre="the IL-6 inhibitor tocilizumab. Two retrospective reviews found that tocilizumab" exact="treatment" post="was associated with a significant reduction in markers of"/>
 <result pre="of T cells against SARS-CoV-2. In line with this hypothesis," exact="treatment" post="of COVID-19 patients with a synthetic biological immune response"/>
 <result pre="platelet counts, fibrinogen and the prothrombin time for the early" exact="diagnosis" post="of bleeding235, although bleeding seems to be rare in"/>
 <result pre="This agent has short-acting anticoagulant effects and can limit viral" exact="infection" post="and replication by inhibiting TMPRSS2 (ref.241). That fact TMPPRSS2"/>
 <result pre="and lymphocyte counts and decreasing D-dimer levels243. Notably, through virtual" exact="screening" post="of an approved drug library, dipyridamole was also found"/>
 <result pre="of a patient with COVID-19-associated ARDS and pneumonia showed that" exact="treatment" post="with a C3 inhibitor was safe and associated with"/>
 <result pre="is required for protection from the highly pathogenic H5N1 influenza" exact="infection" post="and proper viral clearance246, suggesting that C3 inhibition may"/>
 <result pre="oxygen support Oxygen therapy has been used as first-line supportive" exact="treatment" post="for breathing dysfunction and dyspnoea in patients with COVID-19"/>
 <result pre="To date, little is known about the efficacy of this" exact="treatment" post="as most data are derived from uncontrolled case studies"/>
 <result pre="antibodies from convalescent patients. Conclusions Available evidence demonstrates that SARS-CoV-2" exact="infection" post="induces immune dysfunction, widespread endothelial injury, complement-associated coagulopathy and"/>
 <result pre="to thromboembolic complications, it is unlikely that a single individual" exact="treatment" post="will be effective. Although corticosteroids may be able to"/>
 <result pre="pathogenic nature of the disease indicates that multiple avenues of" exact="treatment" post="might be required and major effort should therefore be"/>
 <result pre="Engl. J. Med.20203821199120710.1056/NEJMoa200131631995857 21.HouYJet al.SARS-CoV-2 reverse genetics reveals a variable" exact="infection" post="gradient in the respiratory tractCell2020182429446.e1410.1016/j.cell.2020.05.04232526206 22.ShiYet al.COVID-19 infection: the"/>
 <result pre="J. Legal Med.2020341271127410.1007/s00414-020-02318-9 26.PernazzaAet al.Early histologic findings of pulmonary SARS-CoV-2" exact="infection" post="detected in a surgical specimenVirchows Arch.202010.1007/s00428-020-02829-132915266 27.HuangCet al.Clinical features"/>
 <result pre="in Wuhan, ChinaJAMA Cardiol.2020580281010.1001/jamacardio.2020.095032211816 37.ZangRet al.TMPRSS2 and TMPRSS4 promote SARS-CoV-2" exact="infection" post="of human small intestinal enterocytesSci. Immunol.20205eabc358210.1126/sciimmunol.abc358232404436 38.LamersMMet al.SARS-CoV-2 productively"/>
 <result pre="immune cells in patients with COVID-19Nat. Med.20202684284410.1038/s41591-020-0901-932398875 61.B BostPet al.Host-viral" exact="infection" post="maps reveal signatures of severe COVID-19 patientsCell202018114751488.e1210.1016/j.cell.2020.05.00632479746 62.ShenBet al.Proteomic"/>
 <result pre="of human single-domain antibodies against SARS-CoV-2Cell Host Microbe202027891898.e510.1016/j.chom.2020.04.02332413276 92.ChandrashekarAet al.SARS-CoV-2" exact="infection" post="protects against rechallenge in rhesus macaquesScience202036981281710.1126/science.abc477632434946 93.DengWet al.Primary exposure"/>
 <result pre="Arch.200745434535910.1007/s00424-007-0212-817256154 113.TeuwenLAGeldhofVPasutACarmelietPCOVID-19: the vasculature unleashedNat. Rev. Immunol.20202038939110.1038/s41577-020-0343-032439870 114.VargaZet al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet20203951417141810.1016/S0140-6736(20)30937-532325026 115.OxleyTJet al.Large-vessel stroke as a"/>
 <result pre="2019 epidemic and kidneysKidney Int.20209782482810.1016/j.kint.2020.03.00132204907 171.FarkashEAWilsonAMJentzenJMUltrastructural evidence for direct renal" exact="infection" post="with SARS-CoV-2J. Am. Soc. Nephrol.2020311683168710.1681/ASN.202004043232371536 172.AbbateMRottoliDGianattiACOVID-19 attacks the kidney:"/>
 <result pre="Dis.202022e1328610.1111/tid.1328632279418 200.VincentMJet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 201.CavalcantiABet al.Hydroxychloroquine with or without azithromycin"/>
 <result pre="Netw. Open20203e20885710.1001/jamanetworkopen.2020.885732330277 205.KleynbergRLSchillerGJSecondary hemophagocytic lymphohistiocytosis in adults: an update on" exact="diagnosis" post="and therapyClin. Adv. Hematol. Oncol.20121072673223271259 206.Cruz-TopeteDCidlowskiJAOne hormone, two actions:"/>
 <result pre="pro-inflammatory effects of glucocorticoidsNeuroimmunomodulation201522203210.1159/00036272425227506 207.RussellCDMillarJEBaillieJKClinical evidence does not support corticosteroid" exact="treatment" post="for 2019-nCoV lung injuryLancet202039547347510.1016/S0140-6736(20)30317-232043983 208.WuCet al.Risk factors associated with"/>
 <result pre="multicentre, double-blind, randomised, placebo-controlled trialLancet20153851511151810.1016/S0140-6736(14)62447-825608756 212.TorresAet al.Effect of corticosteroids on" exact="treatment" post="failure among hospitalized patients with severe community-acquired pneumonia and"/>
 <result pre="AKI after cardiac surgeryJ. Am. Soc. Nephrol.2015262947295110.1681/ASN.201408084025952257 218.PonticelliCLocatelliFGlucocorticoids in the" exact="treatment" post="of glomerular diseases: pitfalls and pearlsClin. J. Am. Soc."/>
 <result pre="alpha interferon in chronic hepatitis CHepatology199726112S121S10.1002/hep.5102607209305675 220.AlattarRet al.Tocilizumab for the" exact="treatment" post="of severe coronavirus disease 2019J. Med. Virol.202010.1002/jmv.2596432965715 221.GuaraldiGet al.Tocilizumab"/>
</results>
